Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0596 in Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia
NCT06718270Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0596 in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Adverse Events (AE) after CT0596 infusion at 12 months and Maximum Tolerated Dose and/or dose range at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
CT0596
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06718270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718270.